ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2026
Narrowband-UVB may restore adalimumab efficacy in chronic plaque psoriasis patients: A prospective exploratory cohort study.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologic therapies (BT) have revolutionized psoriasis management, yet secondary treatment failure remains a significant challenge. Narrowband ultraviolet B (NB-UVB) phototherapy is an established treatment with local immunomodulatory effects that may synergize with BT to restore efficacy. Evidence supporting this approach, particularly regarding adalimumab failure, is limited. In this prospective, exploratory cohort study, 11 adults with chronic plaque psoriasis exhibiting secondary loss of response to adalimumab (without anti-adalimumab antibodies) underwent adjunctive NB-UVB phototherapy three times weekly for 25-30 sessions, while continuing adalimumab 40 mg biweekly. Disease severity was assessed using the Psoriasis Area and Severity Index (PASI). Clinical response was defined as ≥ 50% PASI reduction from flare or return to baseline PASI. Mean PASI increased from 4.1 ± 0.7 at baseline to 11.8 ± 1.6 at flare. Following NB-UVB, mean PASI decreased to 6.2 ± 3.2 (p = 0.006). Excluding non-responders, PASI was 4.0 ± 0.5, comparable to pre-flare values. Five patients (45,5%) achieved PASI 50, two of whom (18.2%) achieved PASI 75. Responses were sustained for at least 24 months. DLQI improved from 14.7 ± 2.4 at flare to 5.6 ± 6.2 after NB-UVB (p = 0.005), indicating a substantial reduction in disease burden. NB-UVB was well tolerated, with no significant adverse events. Three non-responders switched to ustekinumab. Adjunctive NB-UVB phototherapy restored adalimumab efficacy in a majority of patients experiencing secondary failure, offering a safe, accessible, and cost-conscious strategy. Larger controlled studies are warranted to confirm efficacy, elucidate mechanisms, and define the role of combination therapy in modern psoriasis management.
Indexed as
Identifiers
41400810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.